Zollinger-Ellison Syndrome: Gastrinomas and Acid Control

Zollinger-Ellison syndrome is a condition in which a tumor called a gastrinoma pumps out excessive amounts of the hormone gastrin, driving the stomach to produce dangerously high levels of acid. The result is severe, recurring peptic ulcers and often chronic diarrhea that resist standard treatments. It is rare, but its consequences are serious, and the path to a correct diagnosis can take years because the early symptoms mimic common acid reflux and ulcer disease. What makes ZES especially challenging is that the gastrinoma itself is a neuroendocrine tumor with malignant potential, so managing the syndrome means tackling both the acid damage and the cancer risk simultaneously.

What Drives the Acid Flood

The root of ZES is a gastrinoma, a small tumor that secretes gastrin in an uncontrolled way. Gastrin is a hormone your body normally uses to tell the stomach to release acid after you eat. In a healthy person the system is self-regulating: acid rises, gastrin drops, and the stomach settles. A gastrinoma ignores those signals entirely. It releases gastrin around the clock, and the levels can climb to many times the normal range.

Gastrin does not just flip a switch on acid production. It stimulates the acid-producing parietal cells directly, and it also triggers the release of histamine from nearby cells, which amplifies acid output further. Over time, the constant gastrin stimulation causes the parietal cells and the histamine-releasing cells to physically multiply, a process that makes the stomach even more capable of churning out acid than it was before the tumor appeared.¹ This is why ZES patients do not just have a little extra acid. They can have basal acid output many times above normal, sometimes exceeding 15 milliequivalents per hour even while fasting.²

How Symptoms Show Up

The hallmark of ZES is peptic ulcers that keep coming back despite apparently adequate treatment. The ulcers can appear in the usual places, the stomach and the first part of the small intestine, but they may also crop up in unusual locations further down the digestive tract, which is a red flag that something beyond ordinary ulcer disease is going on. These ulcers are often multiple, and they resist the healing that a standard course of acid-reducing medication would normally achieve.

Chronic diarrhea is the other major symptom, and it affects a large share of patients. It happens because the massive flood of acid overwhelms the small intestine, damaging its lining, inactivating digestive enzymes, and altering the normal absorption of nutrients and water. Some people with ZES actually present with diarrhea as their main complaint rather than ulcer pain, which can send clinicians down the wrong diagnostic path for months or years. Gastroesophageal reflux disease is also common, driven by the same acid overproduction.³

Why It Takes So Long to Diagnose

ZES is rare enough that most physicians will see very few cases in their careers, and the symptoms overlap heavily with garden-variety acid reflux, peptic ulcer disease, and irritable bowel syndrome. A person who shows up with heartburn and diarrhea is far more likely to receive a prescription for a proton pump inhibitor and a referral for a breath test for H. pylori than to be tested for a gastrinoma. The irony is that PPIs can partially mask ZES by lowering acid output enough to heal ulcers temporarily, which delays the realization that something deeper is wrong.

The diagnostic process begins with measuring fasting serum gastrin. Levels above 100 pg/mL raise suspicion, but the test is not as clean as it sounds. Roughly two-thirds of ZES patients have gastrin values that fall in a range overlapping with more common causes of elevated gastrin, including H. pylori infection, chronic PPI use, and a condition called antral G-cell hyperplasia.⁴ Truly normal gastrin in a suspected ZES patient is exceedingly rare, but a moderately high reading does not seal the diagnosis either. Both PPI therapy and H. pylori can independently raise gastrin and confuse the picture.⁵

The Secretin Stimulation Test

When fasting gastrin levels are ambiguous, which is most of the time, clinicians turn to a provocative test. The secretin stimulation test is the standard. Secretin is a hormone that, in normal physiology, suppresses gastrin release. In someone with a gastrinoma, however, injecting secretin paradoxically causes a sharp spike in gastrin. An increase of 100 ng/L or more after secretin injection is the most sensitive and specific cutoff for confirming ZES.⁶

The test is preferred over older alternatives like calcium infusion because it is faster and more reliable. That said, a negative secretin test does not completely rule ZES out, which is one of the frustrating aspects of diagnosing this syndrome.⁷ If clinical suspicion remains high despite a negative result, physicians generally repeat testing or pursue imaging directly.

Finding the Gastrinoma

Once ZES is biochemically confirmed, the next challenge is pinpointing the tumor. Gastrinomas are most commonly found in the duodenum (the first stretch of the small intestine) or the pancreas, within a region sometimes called the “gastrinoma triangle,” bounded by landmarks on the bile duct, the junction of the duodenum’s second and third parts, and the junction of the pancreatic neck and body.⁸ But gastrinomas do not always cooperate. In a prospective surgical series, tumors were found in locations as varied as lymph nodes around the pancreatic head, the pyloric channel, the jejunum, and even an ovary.⁹

Duodenal gastrinomas tend to be small, averaging under a centimeter, while pancreatic gastrinomas are roughly three times that size on average.¹⁰ That size difference matters because smaller tumors are harder to spot on conventional imaging like CT or MRI. Over the past decade, functional imaging has improved localization dramatically. Gallium-68 DOTATATE PET/CT, which exploits the somatostatin receptors on the surface of neuroendocrine tumor cells, has become the preferred tool. Studies report sensitivity around 93% and specificity around 96% for this technique, making it far more reliable than older methods.¹¹ It is now frequently used not only for initial diagnosis but also for selecting patients who might benefit from targeted radionuclide therapy later on.¹²

Controlling the Acid

Before anyone can think about removing the tumor, the immediate priority is getting the acid under control. Uncontrolled gastric acid in ZES can perforate the stomach or intestinal wall, cause life-threatening bleeding, and destroy the esophageal lining. Proton pump inhibitors are the drugs of choice, but the doses needed are far higher than what you would take for ordinary reflux. Where a typical GERD patient might take 20 to 40 mg of a PPI once a day, ZES patients routinely require 80 to 240 mg daily, often split into multiple doses.¹³

In urgent situations, intravenous PPIs can bring acid output under control quickly. In one study, intravenous pantoprazole reduced acid output within 15 minutes of infusion and achieved full control in every patient within an hour, with an average time to effective suppression of about 41 minutes. Most patients could then be maintained on 80 mg every 12 hours intravenously, though a small fraction needed higher or more frequent dosing.¹⁴ The speed and reliability of PPIs transformed ZES management. Before PPIs existed, total gastrectomy, the complete removal of the stomach, was sometimes the only way to prevent fatal acid damage.

Surgery and the Question of Cure

Acid control keeps patients safe, but it does nothing about the tumor itself, and gastrinomas are neuroendocrine tumors with genuine malignant potential. The question of whether and when to operate has been debated for decades. The current consensus is clear: all patients with sporadic ZES (meaning without the inherited MEN1 syndrome) who have a resectable tumor should be offered surgical exploration.¹⁵

Surgery achieves a biochemical cure, meaning normalization of gastrin levels and no detectable tumor, in roughly half of sporadic ZES patients.¹⁶ That number may sound modest, but a large prospective study demonstrated that surgical exploration increases disease-related survival. The benefit comes not from controlling acid, which PPIs already handle, but from preventing tumor progression and the development of liver metastases.¹⁷ In other words, operating changes the natural history of the cancer itself.

Pancreatic gastrinomas are generally more dangerous than duodenal ones. They are larger at diagnosis, and patients with pancreatic tumors more frequently have liver metastases at the time of surgical exploration.¹⁸ Duodenal tumors, while small and sometimes difficult to find during surgery, tend to spread to lymph nodes rather than the liver, which carries a somewhat better prognosis.

The MEN1 Connection

About one in four ZES patients has the condition as part of a hereditary syndrome called multiple endocrine neoplasia type 1 (MEN1), in which tumors develop in several hormone-producing glands simultaneously. MEN1-associated ZES behaves differently from sporadic ZES in several important ways. MEN1 patients tend to be diagnosed younger, and their primary gastrinomas are typically smaller. Paradoxically, though, they often have multiple tumors rather than a single one, which makes surgical cure much harder.¹⁹

Despite the complexity, MEN1/ZES patients actually live longer on average than those with sporadic ZES. One study found median overall survival of 310 months for MEN1/ZES compared to 168 months for sporadic ZES. MEN1 patients also developed liver metastases but did not develop the extrahepatic metastases (spread to bone or other distant sites) that worsened outcomes in the sporadic group.²⁰

The surgical approach differs for MEN1 patients. Because their gastrinomas are usually multiple and recurrence after resection is the norm, surgery is generally reserved for tumors larger than about 2 to 2.5 centimeters, where the risk of metastatic spread outweighs the near-certainty of recurrence from smaller tumors left behind.²¹

When the Tumor Has Spread

Gastrinomas are malignant in a substantial proportion of cases. Liver metastases are the most consequential form of spread, and the extent of liver involvement is the single strongest predictor of how long someone with ZES will survive. In a large prospective study, the presence of liver metastases alone moderately decreased survival, but the additional development of bone metastases or ectopic Cushing’s syndrome (where the tumor secretes hormones other than gastrin) markedly worsened the outlook.²²

For patients with metastatic gastrinomas that cannot be surgically removed, a treatment called peptide receptor radionuclide therapy (PRRT) has shown encouraging results. PRRT uses radioactive molecules that bind to somatostatin receptors on the tumor surface, delivering targeted radiation. In one series of patients with malignant gastrinomas treated with PRRT, all experienced symptomatic improvement and their gastrin levels dropped dramatically. About half had a partial tumor response, and the remainder achieved disease stabilization. In nearly two-thirds, the antitumor effect persisted for over a year after treatment ended.²³

Long-Term Survival and What Determines It

ZES is not the death sentence it was decades ago. Before effective acid suppression, patients frequently died from complications of their ulcers. Today, virtually all deaths in ZES are related to tumor progression rather than acid damage. Five-year survival for sporadic ZES is around 62%, and for MEN1-associated ZES it reaches approximately 94%. At twenty years, those numbers are 31% and 58% respectively.²⁴

The factors that separate patients with good outcomes from those with poor outcomes are remarkably consistent across studies. Larger primary tumors, pancreatic rather than duodenal location, the presence and extent of liver metastases, and bone metastases all predict shorter survival. Patients who died of ZES-related causes in one large NIH study tended to have bigger tumors, more frequently located in the pancreas, and higher gastrin levels at diagnosis.²⁵

Living with Lifelong PPI Therapy

Because fewer than a third of ZES patients achieve a lasting surgical cure, the majority need to take high-dose PPIs for the rest of their lives. This creates a unique medical situation. ZES patients have been studied as a natural model for what happens when someone takes PPIs at high doses for decades, since they have no choice but to do so.²⁶

In the general population, long-term PPI use has attracted concern about potential links to bone fractures, kidney disease, infections, and nutrient malabsorption. ZES patients represent the extreme end of PPI exposure, both in dose and duration, and they simultaneously deal with chronically elevated gastrin, which itself has theoretical effects on cell growth in the stomach lining. Research on ZES patients has been used to evaluate whether those theoretical risks translate into real clinical problems over many years. The findings from this population are particularly valuable because they help calibrate how worried anyone on long-term PPIs should actually be. The reassuring takeaway so far is that while monitoring is reasonable, the life-threatening acid damage that PPIs prevent in ZES is far more dangerous than the risks of the medication itself.

For patients who cannot undergo surgery or whose tumors recur, the management plan becomes a long-term partnership with a gastroenterologist and an oncologist. Regular monitoring of gastrin levels, periodic imaging to track tumor behavior, and dose adjustments of acid suppression are all part of the routine. The condition demands patience and vigilance, but the tools available today, from high-dose PPIs to DOTATATE imaging to PRRT, have transformed ZES from a frequently fatal syndrome into one where most patients can live for years or decades with a reasonable quality of life.